FDA 483 - Bracco Imaging Spa C/O Bioindustry - April 12, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bracco Imaging Spa C/O Bioindustry identified significant deficiencies in their drug manufacturing operations. The firm failed to adhere to qualified production processes for aseptic filling, leading to deviations in filling duration, product hold time, and filter usage. Additionally, the inspection revealed inadequate environmental monitoring in aseptic processing areas and a lack of proper training for personnel responsible for aseptic setup and microbial sampling.
ID · aefe2e89-89e6-40f1-bf45-c4951b8eb4b9